This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Cancer	AT rich interactive domain 1A (ARID1A); ARID1B	Cell culture studies suggest inhibiting <i>ARID1B</i> could help treat cancers with <i>ARID1A</i> mutations. ARID1A and B are 60% identical and regulate chromatin remodeling as part of the SWI/SNF complex. Mutations in <i>ARID1A</i> have been previously identified in a variety of tumor types. In multiple <i>ARID1A</i> -mutant cancer cell lines, <i>ARID1B</i> -targeting shRNA decreased cell growth compared with control shRNA, leading to the degradation of the SWI/SNF chromatin remodeling complex. Next steps could include designing inhibitors of ARID1B.	Patent and licensing status unavailable	Helming, K.C. <i>et al. Nat. Med.</i> ; published online Feb. 23, 2014; doi:10.1038/nm.3480 Contact: Charles W.M. Roberts, Dana-Farber Cancer Institute, Boston, Mass. e-mail: charles_roberts@dfci.harvard.edu
<i>SciBX</i> 7(9); doi:10.1038/scibx.2014.249 Published online March 6, 2014				